Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

NCT03212404 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell
Malignant Mesothelioma, Advanced
Head and Neck Cancer
Melanoma
Merkel Cell Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Cutaneous Squamous Cell Carcinoma
Non Hodgkin Lymphoma
Endometrial Cancer

Interventions

DRUG: CK-301 (cosibelimab)

Sponsor

Checkpoint Therapeutics, Inc.

Collaborators

[object Object]